(RTTNews.com) – InVivo Therapeutics Holdings (NVIV) announced Tuesday morning that it has enrolled its fifth patient in its pilot study of its Neuro-Spinal Scaffold implant in patients with acute thoracic spinal cord injury.
InVivo Therapeutics gapped up at the open Tuesday and has risen steadily in early trade. Shares are now up 1.21 at $11.06 on above average volume. The stock has broken out to a 2-week high.
